Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.
Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, Birbara C, Box J, Natarajan K, Nuamah I, Li T, Aranda R, Hagerty DT, Dougados M. Genovese MC, et al. Among authors: hagerty dt. N Engl J Med. 2005 Sep 15;353(11):1114-23. doi: 10.1056/NEJMoa050524. N Engl J Med. 2005. PMID: 16162882 Free article. Clinical Trial.
Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies.
Keystone E, Emery P, Peterfy CG, Tak PP, Cohen S, Genovese MC, Dougados M, Burmester GR, Greenwald M, Kvien TK, Williams S, Hagerty D, Cravets MW, Shaw T. Keystone E, et al. Ann Rheum Dis. 2009 Feb;68(2):216-21. doi: 10.1136/ard.2007.085787. Epub 2008 Apr 3. Ann Rheum Dis. 2009. PMID: 18388156 Clinical Trial.
Costimulation blockade with belatacept in renal transplantation.
Vincenti F, Larsen C, Durrbach A, Wekerle T, Nashan B, Blancho G, Lang P, Grinyo J, Halloran PF, Solez K, Hagerty D, Levy E, Zhou W, Natarajan K, Charpentier B; Belatacept Study Group. Vincenti F, et al. N Engl J Med. 2005 Aug 25;353(8):770-81. doi: 10.1056/NEJMoa050085. N Engl J Med. 2005. PMID: 16120857 Free article. Clinical Trial.
Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties.
Larsen CP, Pearson TC, Adams AB, Tso P, Shirasugi N, Strobert E, Anderson D, Cowan S, Price K, Naemura J, Emswiler J, Greene J, Turk LA, Bajorath J, Townsend R, Hagerty D, Linsley PS, Peach RJ. Larsen CP, et al. Am J Transplant. 2005 Mar;5(3):443-53. doi: 10.1111/j.1600-6143.2005.00749.x. Am J Transplant. 2005. PMID: 15707398 Free article.
Emricasan Improves Liver Function in Patients With Cirrhosis and High Model for End-Stage Liver Disease Scores Compared With Placebo.
Frenette CT, Morelli G, Shiffman ML, Frederick RT, Rubin RA, Fallon MB, Cheng JT, Cave M, Khaderi SA, Massoud O, Pyrsopoulos N, Park JS, Robinson JM, Yamashita M, Spada AP, Chan JL, Hagerty DT. Frenette CT, et al. Among authors: hagerty dt. Clin Gastroenterol Hepatol. 2019 Mar;17(4):774-783.e4. doi: 10.1016/j.cgh.2018.06.012. Epub 2018 Jun 18. Clin Gastroenterol Hepatol. 2019. PMID: 29913280 Free article. Clinical Trial.
Emricasan (IDN-6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal Hypertension.
Garcia-Tsao G, Fuchs M, Shiffman M, Borg BB, Pyrsopoulos N, Shetty K, Gallegos-Orozco JF, Reddy KR, Feyssa E, Chan JL, Yamashita M, Robinson JM, Spada AP, Hagerty DT, Bosch J. Garcia-Tsao G, et al. Among authors: hagerty dt. Hepatology. 2019 Feb;69(2):717-728. doi: 10.1002/hep.30199. Epub 2018 Nov 26. Hepatology. 2019. PMID: 30063802 Free PMC article. Clinical Trial.
Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non-alcoholic fatty liver disease.
Shiffman M, Freilich B, Vuppalanchi R, Watt K, Chan JL, Spada A, Hagerty DT, Schiff E. Shiffman M, et al. Among authors: hagerty dt. Aliment Pharmacol Ther. 2019 Jan;49(1):64-73. doi: 10.1111/apt.15030. Epub 2018 Nov 14. Aliment Pharmacol Ther. 2019. PMID: 30430605 Free PMC article. Clinical Trial.
27 results